Eosinophilic Granulomatosis Market : Opportunities and Forecast Assessment, 2021 to 2031 | Genentech Inc., Cephalon Inc., Amgen Inc.

Posted on 2021-03-09 by Future Market Insights, Inc in Healthcare // 0 Comments

Eosinophilic granulomatosis also known as Churg-Strauss syndrome is a rare autoimmune disorder characterized by multiple sign and symptoms such as acute asthma, inflammation, sinusitis, and nerve damage. As per recent data in 2019, the prevalence of eosinophilic granulomatosis ranges from 1/100,000 to 1/70,000 in Europe and it is much more frequent in asthmatic patients (around 1/15,000). Combination of drug therapies are preferred in the treatment of eosinophilic granulomatosis. The classes of medication used to treat eosinophilic granulomatosis are anti-inflammatory drugs, immunosuppressive drugs, biologics andimmune globulin.

For detailed insights on enhancing your product footprint, request for a sample here@ https://www.factmr.com/connectus/sample?flag=S&rep_id=4697

Eosinophilic Granulomatosis Market: Drivers and Restraints

The rising unmet need of therapeutics for eosinophilic granulomatosis, is expected to primarily drive future growth of the eosinophilic granulomatosis market. The major factor driving the growth of eosinophilic granulomatosis market is increasing prevalence of eosinophilic granulomatosis owning to higher incidence of autoimmune diseases across the world. In addition, early diagnosis and treatment adoption is expected to accelerate growth of eosinophilic granulomatosis market.However, poor healthcare access and higher cost of treatment are expected to hamper the future eosinophilic granulomatosis market in the emerging economies.

Eosinophilic Granulomatosis Market: Segmentation

The eosinophilic granulomatosis market can besegmented into drug class, route of administration, distribution channels and geography.

Based on drug class, the global eosinophilic granulomatosis market is segmented as:

Corticosteroids
Immunosuppressive Agents
Biologics
Immune Globulins

Based on route of administration, the global eosinophilic granulomatosis market is segmented as:

Oral
Intravenous
Intramuscular

To receive extensive list of important regions, ask for TOC here@ https://www.factmr.com/connectus/sample?flag=T&rep_id=4697

Based on the distribution channels, the global eosinophilic granulomatosis market is segmented as:

Hospital Pharmacies
Drug Stores
Retail Pharmacies
Online Pharmacies

Eosinophilic Granulomatosis Market: Overview

The eosinophilic granulomatosis market is expected to experience robust growth over the forecast period owing to early diagnosis and rising prevalence of eosinophilic granulomatosis. Higher industry and government spending are resulting into rapid development of novel eosinophilic granulomatosis therapeutics. Among drug class, corticosteroids and biologics are expected to hold the major market share in the eosinophilic granulomatosis market. In 2017, FDA approved first biologics mepolizumabfor Eosinophilic Granulomatosis with Polyangiitis manufactured by the GlaxoSmithKline. Among route of administration segment, oral route of administration segment is expected to be the leading revenue generating segment in eosinophilic granulomatosis market. Among distribution channel segment, hospital and retail pharmacies are accounted for significant market share in the global eosinophilic granulomatosis market owing to higher patient population and convenience.

Pre-Book Right Now for Exclusive Analyst Support @ https://www.factmr.com/checkout/4697/S

Eosinophilic Granulomatosis Market: Key Players

The global market for eosinophilic granulomatosis is consolidated withlarge number of market players. Examples of some of the primary key players operating in the global eosinophilic granulomatosis market are Genentech Inc. (F. Hoffmann-La Roche AG), Cephalon Inc. (Teva Pharmaceutical Industries Ltd.), Amgen Inc., Sanofi S.A., Koninklijke DSM N.V, AstraZeneca plc, Novartis International AG,GlaxoSmithKline LLC, Pharmaceuticals Holdings Corp, Baxter Healthcare Corporation, andamong others

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.

Matched content

Editor’s pick